BOSTON – Vitiligo is a condition that causes the skin to lose pigment and leaves white patches behind. Researchers are now testing a topical cream designed to safely repigment areas of skin. Every ...

For patients with vitiligo, ruxolitinib cream results in greater repigmentation of lesions compared with vehicle control, according to a study published online Oct. 20 in the New England Journal of ...

- Treatment with ruxolitinib cream (Opzelura™) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving ≥75% improvement from baseline in the ...

BID, twice daily; F-PhGVA, facial Physician’s Global Vitiligo Assessment; F-VASI, facial Vitiligo Area Scoring Index; F-VASI50/75/90, ≥50%/≥75%/≥90% ...

Patients with vitiligo will now have access to the first ever at-home therapy for skin repigmentation approved by the Food and Drug Administration. Jim Lee, vice president for Incyte’s head ...

Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body ...

A pair of posters presented at the American Academy of Dermatology 2023 Annual Meeting showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by ...

A US nationwide phase II clinical trial has found that a topical cream was extremely effective in reversing the effects of vitiligo, a relatively common autoimmune disease that causes loss of skin ...

Vitiligo is an autoimmune condition that is actually much more common than you might think. It affects roughly 1% of the population, and is characterised by partial loss of pigmentation in the skin, ...

Superstar Michael Jackson, actor Jon Hamm, fashion model Winnie Harlow. All three had or currently have the condition vitiligo. It's a condition that causes the skin to lose pigment, leaving white ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced positive topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ...